Contravir Pharmaceuticals (NASDAQ:CTRV) is a biopharmaceutical company based in the United States focused on the commercialization of the treatment of Herpes Zoster (Shingles) and Hepatitis B. They currently have an expected catalyst about their Hepatitis B drug Tenofovir Exalidex (CMX157) coming up, they are presenting data during the European Association for the Study of the Liver Annual Meeting (EASL) in Amsterdam. They will be presenting the data from their drug CMX157, it is a prodrug of Gilead's Viread and is also known as Tenofovir Exalidex or TXL for short. Currently I have a strong belief that Contravir Pharmaceuticals is trading at a heavily discounted price to what it should be worth.
